-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
2
-
-
33644848317
-
Hormone refractory prostate cancer: Management and advances
-
Sonpavde G, Hutson TE, Berry WR. Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 2006; 32: 90-100.
-
(2006)
Cancer Treat Rev
, vol.32
, pp. 90-100
-
-
Sonpavde, G.1
Hutson, T.E.2
Berry, W.R.3
-
3
-
-
0038514138
-
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
-
Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-1237.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1232-1237
-
-
Halabi, S.1
Small, E.J.2
Kantoff, P.W.3
-
4
-
-
34447551019
-
Hormonal therapy for prostate cancer
-
Brawer MK. Hormonal therapy for prostate cancer. Rev Urol 2006; Suppl 2: S35-47.
-
(2006)
Rev Urol
, Issue.SUPPL. 2
-
-
Brawer, M.K.1
-
5
-
-
0037024461
-
Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going?
-
Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-818.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 805-818
-
-
Parmiani, G.1
Castelli, C.2
Dalerba, P.3
-
6
-
-
0037379265
-
Modulation of antitumor immune response by hematopoietic cytokines
-
Waller EK, Ernstoff MS. Modulation of antitumor immune response by hematopoietic cytokines. Cancer 2003; 97: 1797-1809.
-
(2003)
Cancer
, vol.97
, pp. 1797-1809
-
-
Waller, E.K.1
Ernstoff, M.S.2
-
7
-
-
33845741035
-
Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients
-
Alessandro S, Miriam L, Annamaria AG, et al. Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate 2007; 67: 1-7.
-
(2007)
Prostate
, vol.67
, pp. 1-7
-
-
Alessandro, S.1
Miriam, L.2
Annamaria, A.G.3
-
8
-
-
33751363704
-
Tumor escape mechanisms in prostate cancer
-
Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56: 81-87.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 81-87
-
-
Miller, A.M.1
Pisa, P.2
-
9
-
-
0032433127
-
The central role of CD4(+) T cells in the antitumor immune response
-
Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
-
(1998)
J Exp Med
, vol.188
, pp. 2357-2368
-
-
Hung, K.1
Hayashi, R.2
Lafond-Walker, A.3
-
10
-
-
0034292406
-
Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
-
Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165: 3797-3803.
-
(2000)
J Immunol
, vol.165
, pp. 3797-3803
-
-
Nouri-Shirazi, M.1
Banchereau, J.2
Bell, D.3
-
11
-
-
0035963379
-
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction
-
Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411: 1058-1064.
-
(2001)
Nature
, vol.411
, pp. 1058-1064
-
-
Ochsenbein, A.F.1
Sierro, S.2
Odermatt, B.3
-
12
-
-
0037460070
-
Complementray role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells
-
Yu P, Spiotto MT, Lee Y, et al. Complementray role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med 2003; 197: 985-995.
-
(2003)
J Exp Med
, vol.197
, pp. 985-995
-
-
Yu, P.1
Spiotto, M.T.2
Lee, Y.3
-
13
-
-
0042629611
-
Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts
-
Ishihara M, Tawara I, Wang L, et al. Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts. Int J Oncol 2003; 22: 1135-1139.
-
(2003)
Int J Oncol
, vol.22
, pp. 1135-1139
-
-
Ishihara, M.1
Tawara, I.2
Wang, L.3
-
14
-
-
31144469922
-
Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines
-
Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 2006; 176: 1447-1455.
-
(2006)
J Immunol
, vol.176
, pp. 1447-1455
-
-
Dolan, B.P.1
Gibbs, K.D.2
Ostrand-Rosenberg, S.3
-
16
-
-
3042844293
-
Cancer immunotherapy: A treatment for the masses
-
Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305: 200-205.
-
(2004)
Science
, vol.305
, pp. 200-205
-
-
Blattman, J.N.1
Greenberg, P.D.2
-
17
-
-
33644697100
-
Prostate cancer immunology: Biology, therapeutics, and challenges
-
Webster WS, Small EJ, Rini B, et al. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol 2005; 23: 8262-8269.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8262-8269
-
-
Webster, W.S.1
Small, E.J.2
Rini, B.3
-
18
-
-
20444467359
-
Technology Insight: Vaccine therapy for prostate cancer
-
Vieweg J, Dannull J. Technology Insight: vaccine therapy for prostate cancer. Nat Clin Pract Urol 2005; 2: 244-251.
-
(2005)
Nat Clin Pract Urol
, vol.2
, pp. 244-251
-
-
Vieweg, J.1
Dannull, J.2
-
19
-
-
33644638927
-
MDX-010 (human anti-CTLA4): A phase 1 trial in hormone refractory prostate carcinoma (HRPC) [Abstract 74]
-
Davis TA, Tchekmedyian S, Korman A, et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC) [Abstract 74]. Am Soc Clin Oncol 2002.
-
(2002)
Am Soc Clin Oncol
-
-
Davis, T.A.1
Tchekmedyian, S.2
Korman, A.3
-
20
-
-
4644253363
-
International meeting on cancer vaccines: How can we enhance efficacy of therapeutic vaccines?
-
Belardelli F, Ferrantini M, Parmiani G, et al. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004; 64: 6827-6830.
-
(2004)
Cancer Res
, vol.64
, pp. 6827-6830
-
-
Belardelli, F.1
Ferrantini, M.2
Parmiani, G.3
-
21
-
-
32944474058
-
Effective cancer therapy through immunomodulation
-
Waldmann TA. Effective cancer therapy through immunomodulation. Annu Rev Med 2006; 57: 65-81.
-
(2006)
Annu Rev Med
, vol.57
, pp. 65-81
-
-
Waldmann, T.A.1
-
22
-
-
0030470404
-
Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
-
Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-380.
-
(1996)
Prostate
, vol.29
, pp. 371-380
-
-
Murphy, G.1
Tjoa, B.2
Ragde, H.3
-
23
-
-
0032526296
-
Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
-
Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44.
-
(1998)
Prostate
, vol.36
, pp. 39-44
-
-
Tjoa, B.A.1
Simmons, S.J.2
Bowes, V.A.3
-
24
-
-
0033987088
-
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients
-
Murphy GP, Snow P, Simmons SJ, et al. Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 2000; 42: 67-72.
-
(2000)
Prostate
, vol.42
, pp. 67-72
-
-
Murphy, G.P.1
Snow, P.2
Simmons, S.J.3
-
25
-
-
0034043167
-
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
-
Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-2182.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2175-2182
-
-
Burch, P.A.1
Breen, J.K.2
Buckner, J.C.3
-
26
-
-
0034554863
-
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
-
Small F.J, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-3903.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3894-3903
-
-
Small, F.J.1
Fratesi, P.2
Reese, D.M.3
-
27
-
-
33646914157
-
Immunologic targeting: How to channel a minimal response for maximal outcome
-
Slovin SF. Immunologic targeting: how to channel a minimal response for maximal outcome. Curr Opin Urol 2006; 16: 179-185.
-
(2006)
Curr Opin Urol
, vol.16
, pp. 179-185
-
-
Slovin, S.F.1
-
28
-
-
0036888238
-
Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients
-
Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002; 102: 390-397.
-
(2002)
Int J Cancer
, vol.102
, pp. 390-397
-
-
Kiessling, A.1
Schmitz, M.2
Stevanovic, S.3
-
29
-
-
0037244743
-
Rational approaches to human cancer immunotherapy
-
Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73: 3-29.
-
(2003)
J Leukoc Biol
, vol.73
, pp. 3-29
-
-
Davis, I.D.1
Jefford, M.2
Parente, P.3
-
30
-
-
2942559009
-
Cancer immunotherapy with mRNA-transfected dendritic cells
-
Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199: 251-263.
-
(2004)
Immunol Rev
, vol.199
, pp. 251-263
-
-
Gilboa, E.1
Vieweg, J.2
-
31
-
-
15844420469
-
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
-
Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 2005; 23: 47-49.
-
(2005)
World J Urol
, vol.23
, pp. 47-49
-
-
Schellhammer, P.F.1
Hershberg, R.M.2
-
32
-
-
0037441817
-
How can we tell when cancer vaccines vaccinate
-
Wolchok JD. How can we tell when cancer vaccines vaccinate. J Clin Oncol 2003; 4: 586-587.
-
(2003)
J Clin Oncol
, vol.4
, pp. 586-587
-
-
Wolchok, J.D.1
-
33
-
-
3242747658
-
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial
-
Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60: 197-204.
-
(2004)
Prostate
, vol.60
, pp. 197-204
-
-
Burch, P.A.1
Croghan, G.A.2
Gastineau, D.A.3
-
34
-
-
4143110212
-
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma
-
Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 2004; 10: 5381-5390.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5381-5390
-
-
Di Nicola, M.1
Carlo-Stella, C.2
Mortarini, R.3
-
35
-
-
4344637057
-
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A phase I/II study
-
Pandha HS, John RJ, Hutchinson J, et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 2004; 94: 412-418.
-
(2004)
BJU Int
, vol.94
, pp. 412-418
-
-
Pandha, H.S.1
John, R.J.2
Hutchinson, J.3
-
36
-
-
27144507469
-
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
-
Mu LJ, Kyte K, Kkvalheim G, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93: 749-756.
-
(2005)
Br J Cancer
, vol.93
, pp. 749-756
-
-
Mu, L.J.1
Kyte, K.2
Kkvalheim, G.3
-
37
-
-
0034328925
-
Gene therapy: Trials and tribulations
-
Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1: 91-99.
-
(2000)
Nat Rev Genet
, vol.1
, pp. 91-99
-
-
Somia, N.1
Verma, I.M.2
-
39
-
-
33751204733
-
Gene therapy. An ethical profile of a new medical territory
-
DOI:10.1002/jgm.979
-
Fuchs M. Gene therapy. An ethical profile of a new medical territory. J Gene Med 2006; 8: 1358-1362. DOI:10.1002/jgm.979.
-
(2006)
J Gene Med
, vol.8
, pp. 1358-1362
-
-
Fuchs, M.1
-
40
-
-
0034800323
-
Gentherapie beim Prostatakarzinom
-
Brill T, Barba M, Breul J, et al. Gentherapie beim Prostatakarzinom. Internist (Berl) 2001; 42: 1328-1345.
-
(2001)
Internist (Berl)
, vol.42
, pp. 1328-1345
-
-
Brill, T.1
Barba, M.2
Breul, J.3
-
41
-
-
0035346833
-
In situ gene therapy for prostate cancer: Immunomodulatory approaches
-
Thompson TC, Timme TL, Ebara S, et al. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther 2001; 1: 481-495.
-
(2001)
Expert Opin Biol Ther
, vol.1
, pp. 481-495
-
-
Thompson, T.C.1
Timme, T.L.2
Ebara, S.3
-
45
-
-
0034171011
-
Gene therapy for prostate cancer at the University of California, Los Angeles: Preliminary results and future directions
-
Pantuck AJ, Zisman A, Belldegrun AS. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol 2000; 18: 143-147.
-
(2000)
World J Urol
, vol.18
, pp. 143-147
-
-
Pantuck, A.J.1
Zisman, A.2
Belldegrun, A.S.3
-
46
-
-
0034927685
-
Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
-
Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12: 883-892.
-
(2001)
Hum Gene Ther
, vol.12
, pp. 883-892
-
-
Belldegrun, A.1
Tso, C.L.2
Zisman, A.3
-
47
-
-
0035199415
-
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy
-
Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001; 12: 1955-1967.
-
(2001)
Hum Gene Ther
, vol.12
, pp. 1955-1967
-
-
Miles, B.J.1
Shalev, M.2
Aguilar-Cordova, E.3
-
48
-
-
0028153727
-
Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs
-
Rosenthal FM, Cronin K, Bannerji R, et al. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 1994; 83: 1289-1298.
-
(1994)
Blood
, vol.83
, pp. 1289-1298
-
-
Rosenthal, F.M.1
Cronin, K.2
Bannerji, R.3
-
49
-
-
12244280810
-
Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma
-
Propper DJ, Chao D, Braybrooke JP, et al. Low-dose IFN-γ induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 2003; 9: 84-92.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 84-92
-
-
Propper, D.J.1
Chao, D.2
Braybrooke, J.P.3
-
50
-
-
0037843509
-
Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge
-
Krishnan L, Sad S, Patel GB, et al. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 2003; 63: 2526-2534.
-
(2003)
Cancer Res
, vol.63
, pp. 2526-2534
-
-
Krishnan, L.1
Sad, S.2
Patel, G.B.3
-
51
-
-
0034699775
-
Cytokine-modulated regulation of helper T cell populations
-
Yates A, Bergmann C, Van Hemmen JL, et al. Cytokine-modulated regulation of helper T cell populations. J Theor Biol 2000; 206: 539-560.
-
(2000)
J Theor Biol
, vol.206
, pp. 539-560
-
-
Yates, A.1
Bergmann, C.2
Van Hemmen, J.L.3
-
53
-
-
33745224089
-
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
-
Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441: 890-893.
-
(2006)
Nature
, vol.441
, pp. 890-893
-
-
Williams, M.A.1
Tyznik, A.J.2
Bevan, M.J.3
-
54
-
-
20144389834
-
Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs
-
Frankenberger B, Pohla H, Noessner E, et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 2005; 11: 1733-1742.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1733-1742
-
-
Frankenberger, B.1
Pohla, H.2
Noessner, E.3
-
55
-
-
20944441967
-
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer
-
Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11: 3353-3362.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3353-3362
-
-
Gulley, J.L.1
Arlen, P.M.2
Bastian, A.3
-
56
-
-
0026541909
-
Phase I trial of interleukin-2 plus gamma-interferon
-
Margolin KA, Doroshow JH, Akman SA, et al. Phase I trial of interleukin-2 plus gamma-interferon. J Immunother 1992; 11: 50-55.
-
(1992)
J Immunother
, vol.11
, pp. 50-55
-
-
Margolin, K.A.1
Doroshow, J.H.2
Akman, S.A.3
-
57
-
-
0029871645
-
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma
-
Kim CJ, Taubenberger JK, Simonis TB, et al. Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. J Immunother Emphasis Tumor Immunol 1996; 19: 50-58.
-
(1996)
J Immunother Emphasis Tumor Immunol
, vol.19
, pp. 50-58
-
-
Kim, C.J.1
Taubenberger, J.K.2
Simonis, T.B.3
-
58
-
-
0033587173
-
Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
-
Palmer K, Moore J, Everard M, et al. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 1999; 10: 1261-1268.
-
(1999)
Hum Gene Ther
, vol.10
, pp. 1261-1268
-
-
Palmer, K.1
Moore, J.2
Everard, M.3
-
59
-
-
0034671326
-
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
-
Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18: 4009-4015.
-
(2000)
J Clin Oncol
, vol.18
, pp. 4009-4015
-
-
Negrier, S.1
Caty, A.2
Lesimple, T.3
-
60
-
-
0035914255
-
IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial
-
Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85: 1130-1136.
-
(2001)
Br J Cancer
, vol.85
, pp. 1130-1136
-
-
Atzpodien, J.1
Kirchner, H.2
Illiger, H.J.3
-
61
-
-
0342368610
-
Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
-
de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2000; 6: 1267-1272.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1267-1272
-
-
de Gast, G.C.1
Klumpen, H.J.2
Vyth-Dreese, F.A.3
-
62
-
-
0032741439
-
Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
-
Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59: 5160-5168.
-
(1999)
Cancer Res
, vol.59
, pp. 5160-5168
-
-
Simons, J.W.1
Mikhak, B.2
Chang, J.F.3
-
63
-
-
0033765794
-
Cancer cells engineered to secrete granulocyte-macrophage colonystimulatihg factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies
-
Nelson WG, Simons JW, Mikhak B, et al. Cancer cells engineered to secrete granulocyte-macrophage colonystimulatihg factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46: S67-S72.
-
(2000)
Cancer Chemother Pharmacol
, vol.46
-
-
Nelson, W.G.1
Simons, J.W.2
Mikhak, B.3
-
64
-
-
0036164844
-
Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer
-
Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89: 19-26.
-
(2002)
BJU Int
, vol.89
, pp. 19-26
-
-
Eaton, J.D.1
Perry, M.J.2
Nicholson, S.3
-
65
-
-
0037673064
-
Genomic medicines for oncology: Early lessons
-
Simons JW. Genomic medicines for oncology: early lessons. J Med Assoc Ga 2003; 92: 35-38.
-
(2003)
J Med Assoc Ga
, vol.92
, pp. 35-38
-
-
Simons, J.W.1
-
66
-
-
20444453277
-
Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables
-
Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469-4478.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4469-4478
-
-
Michael, A.1
Ball, G.2
Quatan, N.3
-
68
-
-
33748162994
-
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer
-
Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006; 24: 419-424.
-
(2006)
Urol Oncol
, vol.24
, pp. 419-424
-
-
Simons, J.W.1
Sacks, N.2
-
69
-
-
33746012881
-
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
-
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3089-3094
-
-
Small, E.J.1
Schellhammer, P.F.2
Higano, C.S.3
-
70
-
-
34447537131
-
-
Available:, accessed: 29 Dec. 2006
-
Available: www4.od.nih.gov/oba/rac/protocol.pdf (accessed: 29 Dec. 2006).
-
-
-
-
71
-
-
0027203411
-
Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
-
Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-1572.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1566-1572
-
-
Scher, H.I.1
Kelly, W.K.2
-
72
-
-
1442290324
-
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group
-
Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22: 537-556.
-
(2004)
J Clin Oncol
, vol.22
, pp. 537-556
-
-
Scher, H.I.1
Eisenberger, M.2
D'Amico, A.V.3
-
73
-
-
0037108840
-
Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen
-
Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62: 5807-5812.
-
(2002)
Cancer Res
, vol.62
, pp. 5807-5812
-
-
Lu, J.1
Celis, E.2
-
74
-
-
0030834459
-
MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma
-
Bander NH, Yao D, Liu H, et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233-239.
-
(1997)
Prostate
, vol.33
, pp. 233-239
-
-
Bander, N.H.1
Yao, D.2
Liu, H.3
-
75
-
-
0037252386
-
Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies
-
Pandha HS, Stockwin LH, Eaton J, et al. Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies. Prostate Cancer Prostatic Dis 2003; 6: 6-11.
-
(2003)
Prostate Cancer Prostatic Dis
, vol.6
, pp. 6-11
-
-
Pandha, H.S.1
Stockwin, L.H.2
Eaton, J.3
-
76
-
-
0034109776
-
Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells
-
Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933.
-
(2000)
Cancer Res
, vol.60
, pp. 1927-1933
-
-
Lee, H.M.1
Timme, T.L.2
Thompson, T.C.3
-
77
-
-
33750341482
-
Dendritic cells cross-dressed with peptide MHC Class I complexes prime CD8+ T Cells
-
Dolan BP, Gibbs KD Jr., Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC Class I complexes prime CD8+ T Cells. J Immunol 2006; 177: 6018-6024.
-
(2006)
J Immunol
, vol.177
, pp. 6018-6024
-
-
Dolan, B.P.1
Gibbs Jr., K.D.2
Ostrand-Rosenberg, S.3
-
78
-
-
34447525833
-
-
Available:, accessed: 29 Dec. 2006
-
Available: www.syfpeithi.de (accessed: 29 Dec. 2006).
-
-
-
-
79
-
-
0032530575
-
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
-
Correale P, Walmsley K, Zaremba S, et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 1998; 161: 3186-3194.
-
(1998)
J Immunol
, vol.161
, pp. 3186-3194
-
-
Correale, P.1
Walmsley, K.2
Zaremba, S.3
-
80
-
-
0031895770
-
Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
-
Salgaller ML, Lodge PA, McLean JG, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998; 35: 144-151.
-
(1998)
Prostate
, vol.35
, pp. 144-151
-
-
Salgaller, M.L.1
Lodge, P.A.2
McLean, J.G.3
-
81
-
-
0034306972
-
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
-
Dannull J, Diener PA, Prilder L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-5528.
-
(2000)
Cancer Res
, vol.60
, pp. 5522-5528
-
-
Dannull, J.1
Diener, P.A.2
Prilder, L.3
-
82
-
-
0035874893
-
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule
-
Trojan A, Witzens M, Schultze JL, et al. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001; 61: 4761-4765.
-
(2001)
Cancer Res
, vol.61
, pp. 4761-4765
-
-
Trojan, A.1
Witzens, M.2
Schultze, J.L.3
-
83
-
-
22244458905
-
Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy
-
Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65: 6435-6442.
-
(2005)
Cancer Res
, vol.65
, pp. 6435-6442
-
-
Machlenkin, A.1
Paz, A.2
Bar Haim, E.3
-
84
-
-
0035182192
-
Efficient identification of novel HLA-A(*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis
-
Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*) 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193: 73-88.
-
(2001)
J Exp Med
, vol.193
, pp. 73-88
-
-
Kessler, J.H.1
Beekman, N.J.2
Bres-Vloemans, S.A.3
-
85
-
-
0033916550
-
Allogeneic vaccination for renal cell carcinoma: Development and monitoring
-
Pohla H, Frankenberger B, Stadlbauer B, et al. Allogeneic vaccination for renal cell carcinoma: development and monitoring. Bone Marrow Transplant 2000; 25(Suppl 2): S83-87.
-
(2000)
Bone Marrow Transplant
, vol.25
, Issue.SUPPL. 2
-
-
Pohla, H.1
Frankenberger, B.2
Stadlbauer, B.3
-
86
-
-
0037408535
-
Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma: Stat3 activation and cyclin D1 overexpression are mutually exclusive events
-
Quintanilla-Martinez L, Kremer M, Specht K, et al. Analysis of signal transducer and activator of transcription 3 (Stat3) pathway in multiple myeloma: Stat3 activation and cyclin D1 overexpression are mutually exclusive events. Am J Pathol 2003; 162: 1449-1461.
-
(2003)
Am J Pathol
, vol.162
, pp. 1449-1461
-
-
Quintanilla-Martinez, L.1
Kremer, M.2
Specht, K.3
-
87
-
-
0036896972
-
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine
-
Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549-4554.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4549-4554
-
-
Hsueh, E.C.1
Essner, R.2
Foshag, L.J.3
-
88
-
-
10744230275
-
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
-
Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363: 594-599.
-
(2004)
Lancet
, vol.363
, pp. 594-599
-
-
Jocham, D.1
Richter, A.2
Hoffmann, L.3
-
89
-
-
22144497779
-
Vaccines in cancer: GVAX, a GM-CSF gene vaccine
-
Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259-274.
-
(2005)
Expert Rev Vaccines
, vol.4
, pp. 259-274
-
-
Nemunaitis, J.1
-
90
-
-
22544458183
-
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer
-
Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4: 55-60.
-
(2005)
Clin Prostate Cancer
, vol.4
, pp. 55-60
-
-
Beinart, G.1
Rini, B.I.2
Weinberg, V.3
-
91
-
-
2542574206
-
CD8+ T cell cross-priming via transfer of proteasome substrates
-
Norbury CC, Basta S, Donohue KB, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004; 304: 1318-1321.
-
(2004)
Science
, vol.304
, pp. 1318-1321
-
-
Norbury, C.C.1
Basta, S.2
Donohue, K.B.3
-
92
-
-
1542357672
-
Cellular protein is the source of cross-priming antigen in vivo
-
Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A 2004; 101: 3035-3040.
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 3035-3040
-
-
Shen, L.1
Rock, K.L.2
-
93
-
-
0035554675
-
The risk of autoimmunity associated with tumor immunotherapy
-
Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001; 2: 789-792.
-
(2001)
Nat Immunol
, vol.2
, pp. 789-792
-
-
Gilboa, E.1
-
94
-
-
0031255311
-
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for immunotherapy of prostate cancer
-
Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113-3117.
-
(1997)
J Immunol
, vol.159
, pp. 3113-3117
-
-
Fong, L.1
Ruegg, C.L.2
Brockstedt, D.3
|